Medical device maker TruScreen has struggled to make progress over the half year to September despite what it described as a strong recovery in its key market in China.
The NZX-listed company, whose product uses opto-electronics to screen for cervical cancer, reported a net loss for the period
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
